In a report released today, Emily Bodnar from H.C. Wainwright reiterated a Buy rating on NovoCure, with a price target of $42.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Emily Bodnar’s rating is based on NovoCure’s strategic leadership transition and anticipated product developments. The appointment of Frank Leonard as CEO, who has extensive experience within the company, is expected to enhance the commercialization and development of TTFields, particularly as the company prepares for significant launches and international expansion in 2026.
Additionally, several upcoming catalysts are expected to drive growth, including FDA approvals for TTFields in locally advanced pancreatic cancer and brain metastases from NSCLC, as well as key data readouts from clinical trials such as TRIDENT and PANOVA-4. These developments, coupled with anticipated reimbursement approvals in Japan and France, position NovoCure for substantial growth and support the Buy rating.
Bodnar covers the Healthcare sector, focusing on stocks such as Olema Pharmaceuticals, AnaptysBio, and Agenus. According to TipRanks, Bodnar has an average return of 7.9% and a 34.70% success rate on recommended stocks.